Alx Oncology Holdings (ALXO) Common Equity (2019 - 2026)

Alx Oncology Holdings' Common Equity history runs 8 years deep, the most recent figure standing at $151.3 million for Q1 2026.

• In Q1 2026, Common Equity rose 71.41% year-over-year to $151.3 million; the TTM figure through Mar 2026 stood at $151.3 million (up 71.41% YoY), while the FY2025 annual figure was $26.0 million, down 77.13% from the prior year.
• Common Equity came in at $151.3 million for Q1 2026 at Alx Oncology Holdings, up from $26.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $343.6 million in Q1 2022 to a low of $26.0 million in Q4 2025.
• A 5-year average of $174.7 million and a median of $164.2 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity slumped 77.13% in 2025 and surged 71.41% in 2026, its largest moves.
• Alx Oncology Holdings' Common Equity stood at $263.5 million in 2022, then decreased by 27.99% to $189.7 million in 2023, then sank by 40.11% to $113.6 million in 2024, then plunged by 77.13% to $26.0 million in 2025, then soared by 482.53% to $151.3 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $151.3 million, $26.0 million, and $44.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison